Identification of novel macropinocytosis inhibitors using a rational screen of Food and Drug Administration-approved drugs

Hui Ping Lin, Bhupesh Singla, Pushpankur Ghoshal, Jessica L. Faulkner, Mary Cherian-Shaw, Paul M O'Connor, Jin-Xiong She, Eric Jacques Belin de Chantemele, Gabor Csanyi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background and Purpose: Macropinocytosis is involved in many pathologies, including cardiovascular disorders, cancer, allergic diseases, viral and bacterial infections. Unfortunately, the currently available pharmacological inhibitors of macropinocytosis interrupt other endocytic processes and have non-specific endocytosis-independent effects. Here we have sought to identify new, clinically relevant inhibitors of macropinocytosis, using an FDA-approved drug library. Experimental Approach: In the present study, 640 FDA-approved compounds were tested for their ability to inhibit macropinocytosis. A series of secondary assays were performed to confirm inhibitory activity, determine IC50 values and investigate cell toxicity. The ability of identified hits to inhibit phagocytosis and clathrin-mediated and caveolin-mediated endocytosis was also investigated. Scanning electron microscopy and molecular biology techniques were utilized to examine the mechanisms by which selected compounds inhibit macropinocytosis. Key Results: The primary screen identified 14 compounds that at ~10 μM concentration inhibit >95% of macropinocytotic solute internalization. Three compounds - imipramine, phenoxybenzamine and vinblastine - potently inhibited (IC50 ≤ 131 nM) macropinocytosis without exerting cytotoxic effects or inhibiting other endocytic pathways. Scanning electron microscopy imaging indicated that imipramine inhibits membrane ruffle formation, a critical early step leading to initiation of macropinocytosis. Finally, imipramine has been shown to inhibit macropinocytosis in several cell types, including cancer cells, dendritic cells and macrophages. Conclusions and Implications: Our results identify imipramine as a new pharmacological tool to study macropinocytosis in cellular and biological systems. This study also suggests that imipramine could be a good candidate for repurposing as a therapeutic agent in pathological processes involving macropinocytosis.

Original languageEnglish (US)
Pages (from-to)3640-3655
Number of pages16
JournalBritish Journal of Pharmacology
Volume175
Issue number18
DOIs
StatePublished - Sep 1 2018

Fingerprint

Imipramine
United States Food and Drug Administration
Pharmaceutical Preparations
Endocytosis
Electron Scanning Microscopy
Pharmacology
Caveolins
Phenoxybenzamine
Clathrin
Vinblastine
Virus Diseases
Pathologic Processes
Phagocytosis
Bacterial Infections
Dendritic Cells
Inhibitory Concentration 50
Molecular Biology
Neoplasms
Macrophages
Pathology

ASJC Scopus subject areas

  • Pharmacology

Cite this

Identification of novel macropinocytosis inhibitors using a rational screen of Food and Drug Administration-approved drugs. / Lin, Hui Ping; Singla, Bhupesh; Ghoshal, Pushpankur; Faulkner, Jessica L.; Cherian-Shaw, Mary; O'Connor, Paul M; She, Jin-Xiong; Belin de Chantemele, Eric Jacques; Csanyi, Gabor.

In: British Journal of Pharmacology, Vol. 175, No. 18, 01.09.2018, p. 3640-3655.

Research output: Contribution to journalArticle

@article{27635504e26445c59564d0f8b03b5aae,
title = "Identification of novel macropinocytosis inhibitors using a rational screen of Food and Drug Administration-approved drugs",
abstract = "Background and Purpose: Macropinocytosis is involved in many pathologies, including cardiovascular disorders, cancer, allergic diseases, viral and bacterial infections. Unfortunately, the currently available pharmacological inhibitors of macropinocytosis interrupt other endocytic processes and have non-specific endocytosis-independent effects. Here we have sought to identify new, clinically relevant inhibitors of macropinocytosis, using an FDA-approved drug library. Experimental Approach: In the present study, 640 FDA-approved compounds were tested for their ability to inhibit macropinocytosis. A series of secondary assays were performed to confirm inhibitory activity, determine IC50 values and investigate cell toxicity. The ability of identified hits to inhibit phagocytosis and clathrin-mediated and caveolin-mediated endocytosis was also investigated. Scanning electron microscopy and molecular biology techniques were utilized to examine the mechanisms by which selected compounds inhibit macropinocytosis. Key Results: The primary screen identified 14 compounds that at ~10 μM concentration inhibit >95{\%} of macropinocytotic solute internalization. Three compounds - imipramine, phenoxybenzamine and vinblastine - potently inhibited (IC50 ≤ 131 nM) macropinocytosis without exerting cytotoxic effects or inhibiting other endocytic pathways. Scanning electron microscopy imaging indicated that imipramine inhibits membrane ruffle formation, a critical early step leading to initiation of macropinocytosis. Finally, imipramine has been shown to inhibit macropinocytosis in several cell types, including cancer cells, dendritic cells and macrophages. Conclusions and Implications: Our results identify imipramine as a new pharmacological tool to study macropinocytosis in cellular and biological systems. This study also suggests that imipramine could be a good candidate for repurposing as a therapeutic agent in pathological processes involving macropinocytosis.",
author = "Lin, {Hui Ping} and Bhupesh Singla and Pushpankur Ghoshal and Faulkner, {Jessica L.} and Mary Cherian-Shaw and O'Connor, {Paul M} and Jin-Xiong She and {Belin de Chantemele}, {Eric Jacques} and Gabor Csanyi",
year = "2018",
month = "9",
day = "1",
doi = "10.1111/bph.14429",
language = "English (US)",
volume = "175",
pages = "3640--3655",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "18",

}

TY - JOUR

T1 - Identification of novel macropinocytosis inhibitors using a rational screen of Food and Drug Administration-approved drugs

AU - Lin, Hui Ping

AU - Singla, Bhupesh

AU - Ghoshal, Pushpankur

AU - Faulkner, Jessica L.

AU - Cherian-Shaw, Mary

AU - O'Connor, Paul M

AU - She, Jin-Xiong

AU - Belin de Chantemele, Eric Jacques

AU - Csanyi, Gabor

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background and Purpose: Macropinocytosis is involved in many pathologies, including cardiovascular disorders, cancer, allergic diseases, viral and bacterial infections. Unfortunately, the currently available pharmacological inhibitors of macropinocytosis interrupt other endocytic processes and have non-specific endocytosis-independent effects. Here we have sought to identify new, clinically relevant inhibitors of macropinocytosis, using an FDA-approved drug library. Experimental Approach: In the present study, 640 FDA-approved compounds were tested for their ability to inhibit macropinocytosis. A series of secondary assays were performed to confirm inhibitory activity, determine IC50 values and investigate cell toxicity. The ability of identified hits to inhibit phagocytosis and clathrin-mediated and caveolin-mediated endocytosis was also investigated. Scanning electron microscopy and molecular biology techniques were utilized to examine the mechanisms by which selected compounds inhibit macropinocytosis. Key Results: The primary screen identified 14 compounds that at ~10 μM concentration inhibit >95% of macropinocytotic solute internalization. Three compounds - imipramine, phenoxybenzamine and vinblastine - potently inhibited (IC50 ≤ 131 nM) macropinocytosis without exerting cytotoxic effects or inhibiting other endocytic pathways. Scanning electron microscopy imaging indicated that imipramine inhibits membrane ruffle formation, a critical early step leading to initiation of macropinocytosis. Finally, imipramine has been shown to inhibit macropinocytosis in several cell types, including cancer cells, dendritic cells and macrophages. Conclusions and Implications: Our results identify imipramine as a new pharmacological tool to study macropinocytosis in cellular and biological systems. This study also suggests that imipramine could be a good candidate for repurposing as a therapeutic agent in pathological processes involving macropinocytosis.

AB - Background and Purpose: Macropinocytosis is involved in many pathologies, including cardiovascular disorders, cancer, allergic diseases, viral and bacterial infections. Unfortunately, the currently available pharmacological inhibitors of macropinocytosis interrupt other endocytic processes and have non-specific endocytosis-independent effects. Here we have sought to identify new, clinically relevant inhibitors of macropinocytosis, using an FDA-approved drug library. Experimental Approach: In the present study, 640 FDA-approved compounds were tested for their ability to inhibit macropinocytosis. A series of secondary assays were performed to confirm inhibitory activity, determine IC50 values and investigate cell toxicity. The ability of identified hits to inhibit phagocytosis and clathrin-mediated and caveolin-mediated endocytosis was also investigated. Scanning electron microscopy and molecular biology techniques were utilized to examine the mechanisms by which selected compounds inhibit macropinocytosis. Key Results: The primary screen identified 14 compounds that at ~10 μM concentration inhibit >95% of macropinocytotic solute internalization. Three compounds - imipramine, phenoxybenzamine and vinblastine - potently inhibited (IC50 ≤ 131 nM) macropinocytosis without exerting cytotoxic effects or inhibiting other endocytic pathways. Scanning electron microscopy imaging indicated that imipramine inhibits membrane ruffle formation, a critical early step leading to initiation of macropinocytosis. Finally, imipramine has been shown to inhibit macropinocytosis in several cell types, including cancer cells, dendritic cells and macrophages. Conclusions and Implications: Our results identify imipramine as a new pharmacological tool to study macropinocytosis in cellular and biological systems. This study also suggests that imipramine could be a good candidate for repurposing as a therapeutic agent in pathological processes involving macropinocytosis.

UR - http://www.scopus.com/inward/record.url?scp=85052125198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052125198&partnerID=8YFLogxK

U2 - 10.1111/bph.14429

DO - 10.1111/bph.14429

M3 - Article

C2 - 29953580

AN - SCOPUS:85052125198

VL - 175

SP - 3640

EP - 3655

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 18

ER -